This transcript has been edited for clarity.
Welcome back. Now I will go over revisions to the final sections of the 2021 American Diabetes Association (ADA) Standards of Care.
Section 9: Pharmacologic Approaches to Glycemic Treatment
Section 9 is the most important part of these standards because it goes through how we should treat our patients with diabetes and hopefully provides some useful detail as to how to approach an individual patient. It is the heart of these guidelines, and it's long and complicated. I encourage you to read the tables and the figures to really get a sense of what this section is all about. I will explain what has changed.
In terms of insulin, we talk about the benefits of using sensor-augmented insulin pumps. We also talk about the concern for overbasalization in patients on insulin therapy — how to avoid this and how to assess for it.
The big change is in Figure 9.1, which now has a dedicated pathway for how to choose treatments for patients with chronic kidney disease (CKD) or heart failure. It starts out the way all of our figures do for the treatment of type 2 diabetes: First-line therapy is metformin
COMMENTARY
"Heart" of the New ADA Guidelines: Pharmacologic Approaches to Glycemic Treatment
Anne L. Peters, MD
DisclosuresJanuary 07, 2021
This transcript has been edited for clarity.
Welcome back. Now I will go over revisions to the final sections of the 2021 American Diabetes Association (ADA) Standards of Care.
Section 9: Pharmacologic Approaches to Glycemic Treatment
Section 9 is the most important part of these standards because it goes through how we should treat our patients with diabetes and hopefully provides some useful detail as to how to approach an individual patient. It is the heart of these guidelines, and it's long and complicated. I encourage you to read the tables and the figures to really get a sense of what this section is all about. I will explain what has changed.
In terms of insulin, we talk about the benefits of using sensor-augmented insulin pumps. We also talk about the concern for overbasalization in patients on insulin therapy — how to avoid this and how to assess for it.
The big change is in Figure 9.1, which now has a dedicated pathway for how to choose treatments for patients with chronic kidney disease (CKD) or heart failure. It starts out the way all of our figures do for the treatment of type 2 diabetes: First-line therapy is metformin
Medscape Diabetes © 2021 WebMD, LLC
Any views expressed above are the author's own and do not necessarily reflect the views of WebMD or Medscape.
Cite this: Anne L. Peters. "Heart" of the New ADA Guidelines: Pharmacologic Approaches to Glycemic Treatment - Medscape - Jan 07, 2021.
Tables
Authors and Disclosures
Authors and Disclosures
Author(s)
Anne L. Peters, MD
Professor, Department of Clinical Medicine, Keck School of Medicine; Director, University of Southern California Westside Center for Diabetes, University of Southern California, Los Angeles, California
Disclosure: Anne L. Peters, MD, has disclosed the following relevant financial relationships:
Serve(d) on the advisory board for: Abbott Diabetes Care; Becton Dickinson; Boehringer Ingelheim Pharmaceuticals, Inc.; Eli Lilly and Company; Lexicon Pharmaceuticals, Inc.; Livongo; Medscape; Merck & Co., Inc.; Novo Nordisk; Omada Health; OptumHealth; sanofi; Zafgen
Received research support from: Dexcom; MannKind Corporation; Astra Zeneca
Serve(d) as a member of a speakers bureau for: Novo Nordisk